Cardiff OncologyNASDAQ: CRDF

- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC -

Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $30.09 billion by 2033; It said that about 50% of mCRC patients harbor the RAS mutation. A new phase 2 investigator-sponsored study, using onvansertib + Nalirifox for the treatment of 1st-line PDAC patients, will be deployed soon.

Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Marc Frahm - TD Cowen Operator Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.

Cardiff Oncology, Inc. (NASDAQ: CRDF) Q1 2024 Results Earnings Conference Call will take place on May 2, 2024 at 4:30 PM ET. The call will be led by Kiki Patel from Investor Relations at Gilmartin Group, with Mark Erlander as CEO and Jamie Levine as CFO. Conference Call Participants include Mark Frahm from TD Cowen, Joseph Catanzaro from Piper Sandler, and Andy Hsieh from William Blair. Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. All participants are currently in a listen-only mode.

Cardiff Oncology (CRDF) reported a quarterly loss of $0.22 per share, which was better than the expected loss of $0.25 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.25 per share in the same quarter last year.

Management will host a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT.

Cardiff Oncology (CRDF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.